We currently don't have sufficient analyst coverage to forecast growth and revenue for Indo-Bangla Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth
15.1%
Revenue growth rate
n/a
Future return on equity
n/a
Analyst coverage
None
Last updated
n/a
Recent future growth updates
No updates
Recent updates
In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as Indo-Bangla Pharmaceuticals has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
DSE:IBP - Analysts future estimates and past financials data (BDT Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2025
221
-26
56
56
N/A
9/30/2025
198
-33
67
67
N/A
6/30/2025
184
-37
58
58
N/A
3/31/2025
91
-46
14
14
N/A
12/31/2024
88
-44
8
11
N/A
9/30/2024
119
-45
11
16
N/A
6/30/2024
177
-41
24
34
N/A
3/31/2024
212
-18
75
88
N/A
12/31/2023
296
-8
83
93
N/A
9/30/2023
338
-10
54
81
N/A
6/30/2023
374
8
43
73
N/A
3/31/2023
375
-35
-3
35
N/A
12/31/2022
416
-22
-1
51
N/A
9/30/2022
447
7
8
48
N/A
7/1/2022
485
25
48
87
N/A
3/31/2022
619
117
49
120
N/A
12/31/2021
654
118
19
121
N/A
9/30/2021
731
135
10
172
N/A
7/1/2021
782
135
-49
151
N/A
3/31/2021
788
105
-112
125
N/A
12/31/2020
843
137
-139
159
N/A
9/30/2020
862
150
-116
179
N/A
6/30/2020
866
156
-133
176
N/A
3/31/2020
853
186
-95
219
N/A
12/31/2019
828
183
-69
200
N/A
9/30/2019
790
170
N/A
156
N/A
6/30/2019
741
155
N/A
167
N/A
3/31/2019
742
134
N/A
128
N/A
12/31/2018
695
117
N/A
129
N/A
9/30/2018
667
102
N/A
110
N/A
6/30/2018
660
98
N/A
87
N/A
3/31/2018
641
89
N/A
103
N/A
6/30/2017
617
88
N/A
79
N/A
3/31/2017
581
93
N/A
31
N/A
6/30/2016
445
59
N/A
14
N/A
7/1/2015
435
60
N/A
75
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if IBP's forecast earnings growth is above the savings rate (4.2%).
Earnings vs Market: Insufficient data to determine if IBP's earnings are forecast to grow faster than the BD market
High Growth Earnings: Insufficient data to determine if IBP's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if IBP's revenue is forecast to grow faster than the BD market.
High Growth Revenue: Insufficient data to determine if IBP's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IBP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/14 16:54
End of Day Share Price
2026/05/14 00:00
Earnings
2025/12/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indo-Bangla Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.